Gene therapy trial aims to zap Hard-to-Treat bladder tumors
NCT ID NCT06668493
Summary
This early-stage trial is testing a new gene therapy called nadofaragene firadenovec for adults with a specific type of low-grade bladder cancer in the upper urinary tract. The main goal is to see if the treatment is safe and tolerable. Doctors will also check if the therapy can completely clear the cancer from the kidney's collecting system within 3 to 6 months after a single dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center - Genitourinary (GU) Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Mayo Clinic
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic - Rochester Minnesota
RECRUITINGRochester, Minnesota, 55905, United States
-
Mayo Clinic - Scottsdale Arizona
RECRUITINGScottsdale, Arizona, 85054, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.